What do the recent American Heart Association/American College of Cardiology Foundation Clinical Practice Guidelines tell us about the evolving management of coronary heart disease in older adults? by Forman, Daniel & Wenger, Nanette K
 What do the recent American Heart Association/American
College of Cardiology Foundation Clinical Practice Guidelines tell




(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Forman, Daniel, and Nanette K Wenger. 2013. “What do the
recent American Heart Association/American College of
Cardiology Foundation Clinical Practice Guidelines tell us about
the evolving management of coronary heart disease in older




Accessed February 19, 2015 2:01:35 PM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:11717578
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-
of-use#LAA
 Journal of Geriatric Cardiology (2013) 10: 123−128 
 ©2013 JGC All rights reserved; www.jgc301.com 
  
http://www.jgc301.com; jgc@jgc301.com | Journal of Geriatric Cardiology 
State-of -the-Art Article    • Open Access • 
 
What do the recent American Heart Association/American College of Cardi-
ology Foundation Clinical Practice Guidelines tell us about the evolving man-
agement of coronary heart disease in older adults? 
 
Daniel Forman1, Nanette K Wenger2 
1Harvard Medical School, Brigham and Women’s Hospital, Boston, MA 02115, USA 
2Emory University School of Medicine, Emory Heart and Vascular Center, Atlanta, GA 30303, USA   
 
Abstract 
Biological aging predisposes older adults to increased cardiovascular disease (CHD) and greater disease complexity. Given the high 
age-related prevalence of CHD and age-related compounding factors, the recently updated American Heart Association/American College of 
Cardiology Foundation CHD-related guidelines increased their focus on older patients. These guidelines are predominately evidence-based 
(using data from quality randomized clinical trials) and are organized to delineate medications and procedures that best treat particular car-
diovascular diseases. While such rationale and thought work well in young and middle aged adults, they become problematic in patients who 
are very old. Data pertaining to adults aged ≥ 80 are virtually absent from most randomized clinical trials, and even in the instances when 
very old patients were included, eligibility criteria typically excluded candidates with co-morbidities and complexities of customary CHD 
patients. While medications and interventions yielding benefit in clinical trials should theoretically produce the greatest benefits for patients 
with high intrinsic risk, age-related cardiovascular complexities also increase iatrogenic risks. Navigating between the potential for high 
benefit and high risk in “evidence-based” cardiovascular management remains a key Geriatric Cardiology challenge. In this review we con-
sider the expanded Geriatric Cardiology content of current guidelines, acknowledging both the progress that has been made, as well as the 
work that still needs to be accomplished to truly address the patient-centered priorities of older CHD patients. 
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1  Introduction  
Biological aging predisposes older adults to cardiovas-
cular disease.[1] In the United States, the population aged 65 
years and older accounts for more than 80% of cardiovas-
cular disease deaths and 85% of cardiovascular disease hos-
pitalizations, including 62% of hospitalizations for myocar-
dial infarction and 77% of hospitalizations for heart fail-
ure.[2,3] Advancing age is also associated with greater car-
diovascular disease complexity. Coronary heart disease 
(CHD) is more frequently associated with other cardiovas-
cular diseases (e.g., with heart failure, arrhythmia, and/or 
valvular heart disease), and also more frequently associated 
with non-cardiac diseases, patterns that tend to complicate 
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management and worsen outcomes.[4] Older CHD patients 
are also more likely to be taking multiple medications, to be 
hampered by physical limitations (cognitive and functional) 
and to be coping with many additional health dynamics (e.g., 
chronic pain, poor sleep) that compound cardiovascular 
risks and pose management challenges.   
Given the high age-related prevalence of CHD and age- 
related compounding factors, the recently updated American 
Heart Association/American College of Cardiology Foun-
dation (ACCF/AHA) CHD-related guidelines included in-
creased focus on older patients. These guidelines are pre-
dominately evidence-based (using data from quality ran-
domized clinical trials) and are organized to delineate 
medications and procedures that best treat particular car-
diovascular diseases.[5] While such rationale and thought 
work well in young and middle aged adults, they become 
problematic in patients who are very old. Data pertaining to 
adults aged ≥ 80 are virtually absent from most randomized 
clinical trials, and even in the instances when very old pa-
tients were included, eligibility criteria typically excluded 
candidates with comorbidities and complexities of custo- 
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mary CHD patients. Therefore, a medication judged to be 
effective according to guidelines criteria may produce unan-
ticipated harm in very old age, particularly for patients with 
multimorbidity, polypharmacy, and other typical age-related 
health complexities. “Geriatric cardiology” addresses age- 
related elements as fundamental components in cardiovas-
cular care. The inclusion of geriatric cardiology perspectives 
to the guidelines corroborates the growing awareness that 
aging broadly impacts management decisions and out-
comes.  
Cardiovascular disease is both more common and more 
perilous as a function of advanced age. While medications 
and interventions yielding benefit in clinical trials should 
theoretically produce the greatest benefits for patients with 
high intrinsic risk, age-related cardiovascular complexities 
also increase iatrogenic risks. Navigating between the po-
tential for high benefit and high risk in “evidence-based” 
cardiovascular management remains a key Geriatric Cardi-
ology challenge.  
2  Stable ischemic heart disease 
The 2012 guideline for the diagnosis and management of 
patients with stable ischemic heart disease[6] defines older 
adults as those > 75 years of age, and includes a small sec-
tion focused specifically on their care. The text acknowl-
edges that older patients are more likely to have diffuse and 
severe disease coronary atherosclerosis with a higher preva-
lence of three-vessel and left main coronary artery disease. 
The guideline recognizes that common co-existing condi-
tions makes diagnosis more difficult, including the limited 
capacity of older adults to exercise and their high prevalence 
of baseline electrocardiographic changes that render exer-
cise test data less reliable. The utility of the Duke Treadmill 
Score as a prognostic index is similarly limited, both be-
cause of physical limitations of most old adults and also due 
to their higher prevalence of stable ischemic heart disease 
that diminishes the utility of a function-based test to stratify 
risk. Relative benefits of imaging modalities to enhance 
diagnosis and prognosis of CHD are highlighted.  
The guidelines cite a number of studies showing the less 
frequent use of evidence-based therapies in older adults 
including early invasive procedures, anti-coagulants, beta 
blockers, and glycoprotein IIb/IIIa antagonists, likely related 
to challenges of pharmacotherapy stemming from poly-
pharmacy (and drug interactions) as well as age-related dif-
ferences in drug bioavailability and elimination. Given these 
concerns, a conservative approach to coronary angiography 
is generally advised, especially given higher age-related 
risks of contrast-induced nephropathy and increased mor-
bidity and mortality risks associated with coronary artery 
bypass graft surgery. 
Randomized controlled trial data comparing guide-
line-based medical therapy with myocardial revasculariza-
tion in older patients are also reviewed. Whereas revascu-
larized patients showed greater improvements in symptoms 
in the early months, improvements were comparable in 
symptoms and other quality-of-life measures in both groups 
over the long term, providing additional rationale for 
non-invasive management. There is considerable evidence 
that elderly patients have higher mortality rates following 
percutaneous coronary intervention (PCI) and coronary ar-
tery bypass graft surgery than do younger patients, but the 
available data are highly variable. Thus, the guideline rec-
ommendation for patients with stable ischemic heart disease 
includes initial management that essentially overlaps with 
guideline-based medical therapy for older adult patients of 
any age. However, given the concerns about higher mortal-
ity rates associated with revascularization, particularly in 
patients older than 75 to 80 years, revascularization is rec-
ommended only after careful consideration of patient pref-
erences and desired outcomes, functional capacity, qual-
ity-of-life and end-of-life issues, as well as therapeutic al-
ternatives.   
3  Unstable angina/Non-ST-elevation myocar-
dial infarction 
The 2012 ACCF/AHA Focused Update[7] incorporated 
into the ACCF/AHA 2007 Guidelines[8] for the Manage-
ment of Patients with Unstable Angina/Non-ST-Elevation 
Myocardial Infarction includes a section that addresses 
older adults as a distinct management process. Five class I 
recommendations are provided: (1) older patients with Un-
stable Angina/Non–ST-Segment Elevation Myocardial In-
farction (UA/NSTEMI) should be evaluated for appropriate 
acute and long-term therapeutic interventions in a similar 
manner as younger patients with UA/NSTEMI, (Level of 
Evidence: A); (2) decisions on management of older pa-
tients with UA/NSTEMI should not be based solely on 
chronologic age but should be patient-centered, with con-
sideration given to general health, functional and cognitive 
status, comorbidities, life expectancy, and patient prefer-
ences and goals, (Level of Evidence: B); (3) attention 
should be given to appropriate dosing (i.e., adjusted by 
weight and estimated creatinine clearance) of pharmacol-
ogical agents in older patients with UA/NSTEMI, because 
they often have altered pharmacokinetics (due to reduced 
muscle mass, renal and/or hepatic dysfunction, and reduced 
volume of distribution) and pharmacodynamics (increased 
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risks of hypotension and bleeding), (Level of Evidence: B); 
(4) older UA/NSTEMI patients face increased early proce-
dural risks with revascularization relative to younger pa-
tients, yet the overall benefits from invasive strategies are 
equal to or perhaps greater in older adults and are recom-
mended, (Level of Evidence: B); and (5) consideration 
should be given to patient and family preferences, qual-
ity-of-life issues, end-of-life preferences, and socio-cultural 
differences in older patients with UA/NSTEMI, Level of 
Evidence: C. 
Overall, the recently updated UA/NSTEMI guidelines 
acknowledge the complexity of older CHD patients, but 
assert that evidence-based standards for younger adults are 
often still effective. However, they also emphasize that 
management of older CHD patients must incorporate 
age-related issues into cardiovascular management choices: 
i.e., medical and cognitive status, bleeding risk and other 
risk of interventions, anticipated life expectancy, and patient 
or family preferences. 
4  STEMI 
The 2013 ACCF/AHA Guideline for the Management of 
STEMI[9] is a revision of the 2009 Focused STEMI Up-
dates.[10] The older population is noted to present special 
challenges for diagnosis and management, including delays 
in or lack of reperfusion, increased risk of antithrombotic 
therapy, and presence of comorbidity and renal impairment 
which require dosing adjustment.  
Although the clinical trials frequently have a limited en-
rollment of older populations, treatments that are effective 
in younger patients are usually indicated in the older adults, 
with the caveat that older adults more often have absolute or 
relative contraindications to their use. The guidelines rec-
ommend appropriate boundaries of care within the context 
of individual co-morbidities, frailty, and advanced-care di-
rectives. Some medications are specifically mentioned as 
not recommended due to excessive iatrogenic risks, i.e., 
prasugrel for PCI treated patients, 300 mg loading dose of 
clopidogrel in fibrinolytic-treated patients.  
In the CRUSADE Quality Improvement Initiative 
(2004−2006) 7% of eligible STEMI patients did not receive 
reperfusion therapy, with the factor most strongly associated 
with lack of providing reperfusion in these patients being 
increasing age.[11] Nonetheless, even very elderly patients 
have reasonable post-infarction outcomes when treated ag-
gressively with reperfusion therapy, although individual 
circumstances vary. 
Both the GWTG Quality Improvement Program and a 
reperfusion acute myocardial infarction initiative in North 
Carolina demonstrated that programs designed to systema-
tize care across integrated regional centers can lessen dis-
parities and improve the care of elderly patients with 
STEMI.[12] Currently, longer delays to Emergency Medical 
activation are common among older adults, often due to 
atypical, symptoms and/or lack of symptom recognition.  
5  PCI 
The 2011 guideline for PCI[13] acknowledges that older 
adults constitute a growing proportion of patients consid-
ered for PCI. In one series examining trends over 25 years, 
the proportion of patients undergoing PCI who were 75–84 
years of age doubled and those older than age 85 years in-
creased fivefold. Older age is a strong predictor of mortality 
following PCI and older adults present with a substantially 
higher clinical risk profile. Nonetheless, the guidelines 
stress that angiographic success rates and clinical benefits of 
PCI in older adults are similar to those in younger patients; 
thus, the higher absolute benefit associated with older age 
compensates for the higher absolute risk of adverse out-
comes. Nonetheless the increased risks of complications 
such as major bleeding and stroke mandate careful consid-
eration of the benefits and risks of PCI for individual elderly 
patients. 
6  Coronary artery bypass graft surgery 
The 2011 guideline for coronary artery bypass graft sur-
gery[14] defines the term “elderly” as ≥ 80 years of age. As 
in prior coronary disease subsets, older adults, compared 
with younger subjects, are more likely to have severe coro-
nary artery disease (left main or multi-vessel disease), left 
ventricular systolic dysfunction, concomitant valvular dis-
ease, and to previously have had a sternotomy. Frequent 
co-morbid conditions include diabetes mellitus, hyperten-
sion, chronic obstructive pulmonary disease, peripheral ar-
terial disease and azotemia. Consequently, elderly patients 
have a higher perioperative risk of morbidity and mortality 
than younger patients.  
Operative mortality among elderly patients ranges from 
2.6% at ages older than 75 to 11% at ages older than 80 
years[15,16] undergoing urgent surgery. In several retrospec-
tive studies, a substantially higher in-hospital mortality rate 
is reported among octogenarians than among younger pa-
tients. In the National Cardiovascular Network, which in-
cluded 4,743 octogenarian patients, the in-hospital mortality 
rate for octogenarians was 8.1% compared with 3% for the 
remaining population.[17] Retrospective studies also showed 
that octogenarians have a higher incidence of neurological 
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complications, renal failure, respiratory failure and gastro-
intestinal complications than younger patients.[15,17,18] Con-
sistently, octogenarians have longer lengths of stay, long 
durations of intensive care, and are less likely to be dis-
charged home. In the New York state registry, the length of 
stay was 8.5 days for patients younger than age 50 years 
compared with 14.1 days for those ≥ 80, with dis-
charge-to-home rates of 96% and 52% respectively.[16] 
Despite their higher rates of in-hospital morbidity and 
mortality, the majority of octogenarians achieve functional 
improvement following coronary artery bypass graft surgery. 
Two studies of patients > 80 years of age demonstrated im-
provements in quality of life.[19,20] In one study, angina relief 
and quality-of-life improvement scores did not differ be-
tween patients older and younger than 75 years of age. Of 
136 octogenarians following coronary artery bypass grafting 
surgery, 81% felt that they were left with little or no disabil-
ity in their daily activities and 93% reported substantial 
symptomatic improvement at an average of 2 years post-
operatively.[19] 
7  Discussion 
While U.S. CHD guidelines have evolved in their spe-
cific inclusion of age-based dimensions of care, many un-
resolved relevant elements of care remain. Even the precise 
definition of age remains ambiguous, with variance between 
the different guidelines in the number of years considered as 
“old age” and/or components of health correlated to years of 
life that impact on management decisions. Likewise, age is 
usually mentioned as a set point, rather than as a continuum 
that can fluctuate in relation to accumulating years as well 
as in relation to variations in aggregate health and social 
dynamics.[4]  
Clinical trial endpoints constituting the basis of most 
guidelines recommendations are also rarely aligned to an 
aging perspective. Whereas most trials underlying CHD 
guidelines assess mortality endpoints, older adults may not 
view length of life as their greatest concern. Health goals for 
many CHD patients with chronic illness include independ-
ence in daily living; improved functional capacity, particu-
larly the ability to ambulate; decreased hospitalizations and 
symptoms, i.e., prolongation of symptom-free life. There-
fore it remains ironic that the concepts of patient-centered 
care or patient preferences which are appropriately empha-
sized as a key component of management choices can rarely 
be informed with relevant data. 
The guidelines often extrapolate from the standards em-
phasized for younger adults with some recommendations 
for precaution (e.g., renal and weight-dose adjustments). 
However, standard recommendations for younger popula-
tions often produce untoward effects that remain relatively 
poorly demarked. For example, beta blockers may limit 
chronotropy and exercise performance and potentially in-
crease the need for pacemaker implantation. Nitrate drugs, 
despite symptom relief, may be associated with an increase 
in fall risk and syncope.  
Other interventions effective in younger patients may 
adversely affect older adults; for example, despite the bene-
fits of drug-eluting stents and intensive anti-platelet therapy 
for younger adults,[21] they substantially increase the bleed-
ing risk at elderly age. This is particularly complicated for 
older adults prone to atrial fibrillation and thromboembolic 
disease for which anti-thrombin therapy may be indicated, 
further exacerbating bleeding risk. 
Perhaps under-emphasized in all guidelines is the neces-
sity for patient education designed to foster adherence to 
medications, diet, physical activity and other health-pro-
moting behaviors. It remains ironic that trials often do not 
collect data most pertinent to older patients’ concerns, but it 
is likely that if patients understood which medications best 
achieved independence, function, and high quality of life, it 
would reinforce compliance. Patient and family/caregiver 
education is highly relevant for older adults.  
Cardiac rehabilitation services also merit added emphasis 
as a component of CHD care that is particularly likely to 
benefit the many older CHD patients. Paradoxically, cardiac 
rehabilitation is substantially under-utilized among older 
adults with CHD despite strong evidence that facility and/or 
home-based cardiac rehabilitation programs lessen morbid-
ity and mortality, improve quality of life and functional ca-
pacity, and decrease readmissions and healthcare costs in 
frail to robust older adults.[22] Physician recommendation is 
the strongest determinant of cardiac rehabilitation utiliza-
tion. 
As the guidelines are serially updated, it is likely the fo-
cus and sophistication in relation to age will grow. Tiered 
management, stratified to better account for a continuum of 
comorbidity, frailty, medications, and other components of 
health will likely evolve, adapting standards of evi-
dence-based care to older adults. Specific medication and 
procedural strategies to improve CHD management in rela-
tion to age will also likely evolve, targeting goals to mitigate 
bleeding and other iatrogenic risks without forgoing thera-
peutic benefits. Diagnostic sensitivity and specificity will 
also likely improve, potentially linking functional and/or 
serological indices to imaging to better predict which older 
CHD patients may benefit from therapy despite higher 
age-related therapeutic risks. The consistent inclusion of age 
as a relevant dimension of care appears an important first 
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step toward improved management of the burgeoning 
population of senior adults who are intrinsically prone to 
cardiovascular disease. 
8  Summary 
A patient-centered approach, i.e., management personal-
ized to each patient’s situation, is pivotal in the diagnostic 
and therapeutic considerations of coronary heart disease in 
older adults. 
A systematic approach is requisite to incorporate 
age-related complexities into clinical decision-making. Car-
diovascular risks must be assessed in the context of aggre-
gated age-related risks, determining realistic goals that in-
corporate each patient’s overall health circumstances to 
determine the risks and the benefits of specific options of 
care. These include cardiac and non-cardiac co-morbidities, 
functional capacity (physical and cognitive), pain, and qual-
ity of life factors, all highly relevant in selecting patients 
most likely to benefit from different therapeutic choices. 
Patient-centered treatment goals must also address qual-
ity of life, function, independence, and avoidance of adverse 
events. More data are needed from a broad range of older 
adults to better determine specific thresholds for medical 
and invasive interventions, development of strategies to 
minimize adverse events, and the incorporation of complex 
co-morbidities into risk/benefit ratios. 
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